Companies Cryptocurrencies
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals Inc
Exchange: NasdaqGM
IPO Date: 27/01/2005
CEO: Ms. Nancy Lurker
Biotechnology Healthcare 🔗
  • EYPT
  • 11.44
  • 329128800
    market cap
  • 0.14999962
If you bought

shares of EyePoint Pharmaceuticals Inc (EYPT) on
You would have made
Old Price $12 Current Price $12

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 55 full-time employees. The firm has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.

Address: 480 Pleasant St Ste B300 Watertown MASSACHUSETTS 02472

Stay updated.